Wormin (Tablets) Instructions for Use
Marketing Authorization Holder
Cadila Pharmaceuticals Ltd. (India)
ATC Code
P02CA01 (Mebendazole)
Active Substance
Mebendazole (Rec.INN registered by WHO)
Dosage Form
| Wormin | Tablets 100 mg: 6 pcs. |
Dosage Form, Packaging, and Composition
Tablets are round, flat, orange in color, with beveled edges and a vanillin odor.
| 1 tab. | |
| Mebendazole | 100 mg |
6 pcs. – blisters (1) – cardboard packs.
Clinical-Pharmacological Group
Anthelmintic drug
Pharmacotherapeutic Group
Anthelmintic agents; agents for the treatment of nematode infections; benzimidazole derivatives
Pharmacological Action
Broad-spectrum anthelmintic agent; most effective against enterobiasis. It causes irreversible impairment of glucose utilization in the helminth’s body and inhibits ATP synthesis.
Pharmacokinetics
It is practically not absorbed from the gastrointestinal tract. Plasma protein binding is 90%. It is unevenly distributed in organs, accumulates in adipose tissue, liver, and helminth larvae. In the liver, it is metabolized to a 2-amino derivative.
The half-life (T1/2) is 2.5-5.5 hours. More than 90% of the dose is excreted in the feces unchanged. The absorbed portion (5-10%) is excreted by the kidneys.
Indications
Enterobiasis, ascariasis, ancylostomiasis, strongyloidiasis, trichuriasis, trichinellosis, taeniasis, echinococcosis, alveolar echinococcosis, intestinal capillariasis, gnathostomiasis, mixed helminthiases.
ICD codes
| ICD-10 code | Indication |
| B67 | Echinococcosis |
| B68 | Taeniasis |
| B75 | Trichinellosis |
| B76 | Ancylostomiasis |
| B77 | Ascariasis |
| B78 | Strongyloidiasis |
| B79 | Trichuriasis (trichocephaliasis) |
| B80 | Enterobiasis |
| B81.1 | Intestinal capillariasis |
| B81.4 | Intestinal helminthiases of mixed etiology |
| B83.1 | Gnathostomiasis |
| ICD-11 code | Indication |
| 1F62 | Ascariasis |
| 1F63.0 | Intestinal capillariasis |
| 1F65 | Enterobiasis |
| 1F67 | Gnathostomiasis |
| 1F68 | Hookworm diseases |
| 1F6B | Strongyloidiasis |
| 1F6E | Trichinellosis |
| 1F6G | Trichuriasis |
| 1F73.Z | Echinococcosis, unspecified |
| 1F76.Z | Taeniasis, unspecified |
| 1F9Z | Helminthiases, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For adults and children over 10 years of age with enterobiasis – a single dose of 100 mg.
For children aged 2 to 10 years – a single dose of 25-50 mg. In case of a high probability of reinvasion, the dose is repeated after 2-4 weeks at the same dose.
Simultaneous treatment of all family members is recommended.
For ascariasis, trichuriasis, ancylostomiasis, taeniasis, strongyloidiasis, and mixed helminthiases – 100 mg in the morning and evening for 3 days. For trichinellosis – 200-400 mg 3 times/day for 3 days, and from the 4th to the 10th day – 400-500 mg 3 times/day. For echinococcosis – 500 mg 2 times/day for the first 3 days, then at the same dose 3 times/day for the next 3 days. Subsequently, it is used at a dose of 25-30 mg/kg/day in 3-4 divided doses.
Adverse Reactions
From the digestive system rarely – nausea, abdominal pain; with long-term use at high doses, vomiting, diarrhea, transient increase in the activity of liver transaminases in the blood serum are possible.
From the central nervous system rarely – dizziness; with long-term use at high doses – headache.
From the hematopoietic system with long-term use at high doses, leukopenia, anemia, eosinophilia are possible.
From the urinary system with long-term use at high doses – hematuria, cylindruria.
Other with long-term use at high doses – allergic reactions, hair loss.
Contraindications
Severe liver dysfunction, pregnancy, lactation (breastfeeding), children under 2 years of age, hypersensitivity to mebendazole.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and lactation (breastfeeding).
Use in Hepatic Impairment
Contraindicated in severe liver dysfunction.
Pediatric Use
Contraindicated in children under 2 years of age.
Special Precautions
With long-term use, it is necessary to monitor the peripheral blood picture, liver and kidney function.
Avoid alcohol consumption for 24 hours after taking mebendazole.
Do not use a laxative after taking mebendazole.
Periodic examination of anal swabs and feces after the end of treatment is mandatory (therapy is considered effective in the absence of helminths or their eggs for 7 subsequent days).
Drug Interactions
Mebendazole reduces the need for insulin in patients with diabetes mellitus.
Concomitant use of mebendazole with lipophilic substances should be avoided. With simultaneous use, cimetidine may increase, and carbamazepine and other metabolism inducers may decrease the concentration of mebendazole in the blood.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Mildronate capsules 500mg, 90pcs
OKI, sachets 80mg 2g, 12pcs
Daivobet, ointment, 30g 